For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, KalVista Pharmaceuticals Inc (NASDAQ: KALV) closed at $9.33 up 0.65% from its previous closing price of $9.27. In other words, the price has increased by $0.65 from its previous closing price. On the day, 0.53 million shares were traded. KALV stock price reached its highest trading level at $9.47 during the session, while it also had its lowest trading level at $9.01.
Ratios:
For a deeper understanding of KalVista Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.87 and its Current Ratio is at 6.87. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 07 ’25 when Venrock Healthcare Capital Par bought 73,649 shares for $9.29 per share. The transaction valued at 684,199 led to the insider holds 5,086,445 shares of the business.
Venrock Healthcare Capital Par bought 26,703 shares of KALV for $245,134 on Feb 11 ’25. The 10% Owner now owns 5,117,285 shares after completing the transaction at $9.18 per share. On Feb 10 ’25, another insider, Venrock Healthcare Capital Par, who serves as the 10% Owner of the company, bought 4,137 shares for $9.14 each. As a result, the insider paid 37,812 and bolstered with 5,090,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 461069952 and an Enterprise Value of 240798368.
Stock Price History:
The Beta on a monthly basis for KALV is 0.81, which has changed by -0.37195122 over the last 52 weeks, in comparison to a change of 0.20652604 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $16.88, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 5.30%, while the 200-Day Moving Average is calculated to be -16.37%.
Shares Statistics:
For the past three months, KALV has traded an average of 368.68K shares per day and 315130 over the past ten days. A total of 43.27M shares are outstanding, with a floating share count of 34.81M. Insiders hold about 29.56% of the company’s shares, while institutions hold 73.50% stake in the company. Shares short for KALV as of 1731628800 were 7370968 with a Short Ratio of 19.34, compared to 1728950400 on 6810297. Therefore, it implies a Short% of Shares Outstanding of 7370968 and a Short% of Float of 16.93.
